A study to determine safety of Durvalumab after sequential chemo radiation in patients with unresectable Stage III Non-Small Cell Lung Cancer

Study identifier:D4194C00006

ClinicalTrials.gov identifier:NCT03693300

EudraCT identifier:2018-002220-16

CTIS identifier:N/A

Study Complete

Official Title

A Phase II, Open-Label, Multi-Centre, International Safety Study of Durvalumab Following Sequential Chemotherapy and Radiation Therapy in Patients with Stage III, Unresectable Non-Small Cell Lung Cancer (PACIFIC 6)

Medical condition

Non-small cell lung cancer (NSCLC)

Phase

Phase 2

Healthy volunteers

No

Study drug

Durvalumab

Sex

All

Actual Enrollment

117

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 16 Apr 2019
Primary Completion Date: 13 Dec 2022
Study Completion Date: 21 Apr 2023

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jul 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria